PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

HR+/HER2- breast cancer involves tumor cells that test positive for hormone receptors and negative for HER2 proteins. Cancer cells with estrogen or progesterone hormone receptors can grow in response ...

hypokalemia or QT prolongation – serious adverse events that can arise in patients taking currently approved medications – ...

MR = Mineralocorticoid receptor; PR = Progesterone receptor. The relative binding affinity (%) of the main progestins discussed in this paper for the different steroid receptors is indicated.

Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. Some types of breast cancer cells use ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

Corcept Therapeutics (CORT) announced that the FDA filed its New Drug Application (NDA) submission for its proprietary, selective cortisol ...